Abstract

ObjectivesTo simulate clinical deployment, evaluate performance, and establish quality assurance of a deep learning algorithm (U-Net) for detection, localization, and segmentation of clinically significant prostate cancer (sPC), ISUP grade group ≥ 2, using bi-parametric MRI.MethodsIn 2017, 284 consecutive men in active surveillance, biopsy-naïve or pre-biopsied, received targeted and extended systematic MRI/transrectal US-fusion biopsy, after examination on a single MRI scanner (3 T). A prospective adjustment scheme was evaluated comparing the performance of the Prostate Imaging Reporting and Data System (PI-RADS) and U-Net using sensitivity, specificity, predictive values, and the Dice coefficient.ResultsIn the 259 eligible men (median 64 [IQR 61–72] years), PI-RADS had a sensitivity of 98% [106/108]/84% [91/108] with a specificity of 17% [25/151]/58% [88/151], for thresholds at ≥ 3/≥ 4 respectively. U-Net using dynamic threshold adjustment had a sensitivity of 99% [107/108]/83% [90/108] (p > 0.99/> 0.99) with a specificity of 24% [36/151]/55% [83/151] (p > 0.99/> 0.99) for probability thresholds d3 and d4 emulating PI-RADS ≥ 3 and ≥ 4 decisions respectively, not statistically different from PI-RADS. Co-occurrence of a radiological PI-RADS ≥ 4 examination and U-Net ≥ d3 assessment significantly improved the positive predictive value from 59 to 63% (p = 0.03), on a per-patient basis.ConclusionsU-Net has similar performance to PI-RADS in simulated continued clinical use. Regular quality assurance should be implemented to ensure desired performance.Key Points• U-Net maintained similar diagnostic performance compared to radiological assessment of PI-RADS ≥ 4 when applied in a simulated clinical deployment.• Application of our proposed prospective dynamic calibration method successfully adjusted U-Net performance within acceptable limits of the PI-RADS reference over time, while not being limited to PI-RADS as a reference.• Simultaneous detection by U-Net and radiological assessment significantly improved the positive predictive value on a per-patient and per-lesion basis, while the negative predictive value remained unchanged.

Highlights

  • Materials and methodsThis retrospective analysis was performed in a previously unreported cohort of men undergoing MRI–transrectal US (MR/ TRUS) fusion biopsy

  • All men had clinical indication for biopsy based on prostate-specific antigen (PSA) elevation, clinical examination, or participation in our active surveillance program; were biopsied between January 2017 and December 2017; and were included if they met the following criteria: (a) imaging performed at our main institutional 3-T MRI system and (b) MRI/TRUS-fusion biopsy performed at our institution

  • We examined the effect of co-occurrent detection of sPCpositive men, biopsy sextants, and Prostate Imaging Reporting and Data System (PI-RADS) lesions by U-Net and radiologists on the positive (PPV) and negative predictive value (NPV) using a test based on relative predictive values implemented in the R package DTComPair [19, 20]

Read more

Summary

Introduction

This retrospective analysis was performed in a previously unreported cohort of men undergoing MRI–transrectal US (MR/ TRUS) fusion biopsy. All men had clinical indication for biopsy based on prostate-specific antigen (PSA) elevation, clinical examination, or participation in our active surveillance program; were biopsied between January 2017 and December 2017; and were included if they met the following criteria: (a) imaging performed at our main institutional 3-T MRI system and (b) MRI/TRUS-fusion biopsy performed at our institution. We have recently developed and validated a deep learning model based on the U-Net [10] architecture that demonstrated comparable performance to clinical radiological assessment [11]. Its clinical utility should be evaluated by continued clinical application in consecutive patients, to gain further insights into important aspects of AI deployment into clinical practice

Objectives
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call